Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis

被引:0
作者
J. D. Ringe
A. Dorst
H. Faber
E. Schacht
V. W. Rahlfs
机构
[1] Leverkusen Clinic,Medical Clinic 4
[2] Balgrist University Clinic,Metabolic Bone Disease Unit
[3] idv Datenanalyse und Versuchsplanung,undefined
来源
Rheumatology International | 2004年 / 24卷
关键词
Alfacalcidol; Glucocorticoids; Osteoporosis;
D O I
暂无
中图分类号
学科分类号
摘要
Supplementation therapy with plain vitamin D plus calcium is in general regarded as effective prevention or first-step treatment of glucocorticoid-induced osteoporosis (GIOP). The aim of our study was to compare the therapeutic efficacy of the D-hormone analog alfacalcidol with plain vitamin D in patients with established GIOP with or without vertebral fractures. Patients on long-term glucocorticoid (GC) therapy were included as matched pairs to receive randomly either 1 μg alfacalcidol plus 500 mg calcium per day (group A, n=103) or 1,000 IU vitamin D3 plus 500 mg calcium (group B, n=101). The two groups were well matched in terms of mean age, sex ratio, mean height and weight, daily dosage, and duration of GC therapy, and the percentages of the three underlying diseases included chronic obstructive pulmonary disease, rheumatoid arthritis, and polymyalgia rheumatica. The baseline mean bone mineral density (BMD) values at the lumbar spine for the two groups were −3.26 (alfacalcidol) and −3.25 (vitamin D3) and, at the femoral neck, −2.81 and −2.84, respectively (T scores). Rates of prevalent vertebral and nonvertebral fractures did not differ between groups. During the 3-year study, we observed a median percentage increase of BMD at the lumbar spine of 2.4% in group A and a loss of 0.8% in group B (P<0.0001). There also was a larger median increase at the femoral neck in group A (1.2%) than in group B (0.8%) (P<0.006). The 3-year rates of patients with at least one new vertebral fracture were 9.7% among those assigned to the alfacalcidol group and 24.8% in the vitamin D group (risk reduction 0.61, 95% CI 0.24–0.81, P=0.005). The 3-year rates of patients with at least one new nonvertebral fracture were 15% in the alfacalcidol group and 25% in the vitamin D group (risk reduction 0.41, 95% CI 0.06–0.68, P=0.081). The 3-year rates of patients with at least one new fracture of any kind were 19.4% among those treated with alfacalcidol and 40.65% with vitamin D (risk reduction 0.52, 95% CI 0.25–0.71, P=0.001). In accordance with the observed fracture rates, the alfacalcidol group showed a substantially larger decrease in back pain than the plain vitamin D group (P<0.0001). Generally, side effects in both groups were mild, and only three patients in the alfacalcidol group and two in the vitamin D group had moderate hypercalcemia. We conclude that alfacalcidol plus calcium is highly superior to plain vitamin D3 plus calcium in the treatment of established GIOP.
引用
收藏
页码:63 / 70
页数:7
相关论文
共 31 条
  • [1] Schacht undefined(1999)undefined Calcif Tissue Int 65 317-undefined
  • [2] Cantorna undefined(1998)undefined J Nutr 128 68-undefined
  • [3] DeLuca undefined(2001)undefined FASEB J 15 2579-undefined
  • [4] Andjelkovic undefined(1999)undefined Clin Exp Rheumatol 17 453-undefined
  • [5] Van undefined(1996)undefined Transplantation 61 1495-undefined
  • [6] Reginster undefined(1999)undefined Osteoporos Int 9 75-undefined
  • [7] Sambrook undefined(1993)undefined N Engl J Med 328 1747-undefined
  • [8] Sambrook undefined(2000)undefined J Bone Miner Res 15 1818-undefined
  • [9] Adachi undefined(1996)undefined J Rheumatol 23 995-undefined
  • [10] Buckley undefined(1996)undefined Ann Intern Med 125 961-undefined